Final answer:
Rifamycin inhibits transcription by binding to the beta-subunit of bacterial RNA polymerase, thus preventing the initiation of transcription and offering selective toxicity against bacteria, useful in treating tuberculosis.
Step-by-step explanation:
The effect of rifamycin on transcription is that it binds to the beta-subunit of RNA polymerase and blocks the exit channel, which prevents initiation of transcription. Specifically, rifampin, a semisynthetic member of the rifamycin family, inhibits bacterial RNA polymerase activity by binding to this subunit. The selectivity of this mechanism allows it to be used as a treatment against infections, particularly for mycobacteria that cause tuberculosis, while providing selective toxicity against bacterial cells over eukaryotic cells.